GlassScriptPhysician profile
Salma Akter
NPI 1205097904
$8,592.66
in general payments reported to CMS, 2019-2025
24 companies · $2,282 in 2025
The $2,282 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,168 · 2020: $283 · 2022: $168 · 2023: $454 · 2024: $4,237 · 2025: $2,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,988 · Food and Beverage: $2,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,988.31 |
| Food and Beverage | $2,985.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,446.25 | 2024-2025 | Advisa Dr Mri Surescan, Azure Xt Dr Mri Surescan, Linq II |
| Boston Scientific Corporation | $1,843.04 | 2025 | General - Therapies, Ingevity+, Accolade Sr |
| Abbott Laboratories | $1,242.30 | 2019-2024 | Jot Dx, Assurity, Confirm Rx |
| Pfizer INC. | $425.95 | 2022-2025 | |
| Amgen INC. | $388.40 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $194.52 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.15 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $157.60 | 2023-2025 | Farxiga |
| Edwards Lifesciences Corporation | $133.17 | 2022-2024 | |
| Astellas Pharma US INC | $116.79 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $91.54 | 2022-2025 | Camzyos |
| Regeneron Healthcare Solutions, INC. | $63.86 | 2019 | |
| Lilly USA, LLC | $55.91 | 2025 | Zepbound, Mounjaro |
| Esperion Therapeutics, INC. | $38.46 | 2024 | Nexletol |
| Scpharmaceuticals INC. | $30.78 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $30.49 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $30.44 | 2023 | Verquvo |
| Shire North American Group INC | $24.89 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.93 | 2025 | Lifevest |
| Novo Nordisk INC | $20.66 | 2024 | Wegovy |
| Lantheus Medical Imaging, INC. | $16.34 | 2019 | |
| Medtronic Vascular, INC. | $16.31 | 2019 | |
| Gilead Sciences, INC. | $13.98 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $12.90 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salma Akter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.